NZ577731A - Compositions and methods for treatment of multiple sclerosis - Google Patents
Compositions and methods for treatment of multiple sclerosisInfo
- Publication number
- NZ577731A NZ577731A NZ577731A NZ57773109A NZ577731A NZ 577731 A NZ577731 A NZ 577731A NZ 577731 A NZ577731 A NZ 577731A NZ 57773109 A NZ57773109 A NZ 57773109A NZ 577731 A NZ577731 A NZ 577731A
- Authority
- NZ
- New Zealand
- Prior art keywords
- multiple sclerosis
- microparticle
- treatment
- mis416
- linked
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 238000011282 treatment Methods 0.000 title claims description 70
- 238000000034 method Methods 0.000 title description 12
- 239000011859 microparticle Substances 0.000 claims abstract description 62
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims abstract description 45
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 21
- 239000013543 active substance Substances 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 208000024891 symptom Diseases 0.000 claims description 15
- 108010050904 Interferons Proteins 0.000 claims description 14
- 102000014150 Interferons Human genes 0.000 claims description 14
- 230000000750 progressive effect Effects 0.000 claims description 12
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 10
- 229940047124 interferons Drugs 0.000 claims description 9
- 229960001156 mitoxantrone Drugs 0.000 claims description 9
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 9
- 206010053395 Progressive multiple sclerosis Diseases 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 230000003442 weekly effect Effects 0.000 claims description 8
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 7
- 229960003776 glatiramer acetate Drugs 0.000 claims description 7
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 6
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims description 6
- 238000011262 co‐therapy Methods 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims description 3
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 22
- 208000020154 Acnes Diseases 0.000 abstract 1
- 241001648298 Propionivibrio Species 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 48
- 201000010099 disease Diseases 0.000 description 45
- 210000002683 foot Anatomy 0.000 description 23
- 230000006698 induction Effects 0.000 description 18
- 201000002491 encephalomyelitis Diseases 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 14
- 230000006872 improvement Effects 0.000 description 13
- 230000035807 sensation Effects 0.000 description 13
- 230000004044 response Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 210000002414 leg Anatomy 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 102000006386 Myelin Proteins Human genes 0.000 description 7
- 108010083674 Myelin Proteins Proteins 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 210000005012 myelin Anatomy 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 6
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 6
- 230000006052 T cell proliferation Effects 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 210000003050 axon Anatomy 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 229960005027 natalizumab Drugs 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 230000001934 delay Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 108010005716 Interferon beta-1a Proteins 0.000 description 3
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- 229940090016 tegretol Drugs 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 206010056465 Food craving Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 108010005714 Interferon beta-1b Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000961 alloantigen Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 229940003504 avonex Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 229940038717 copaxone Drugs 0.000 description 2
- 210000004544 dc2 Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010242 retro-orbital bleeding Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 1
- MWTAHJPEYZBMCZ-FLLNTKIGSA-N (2s)-2-aminopropanoic acid;(4r)-4,5-diamino-5-oxopentanoic acid Chemical compound C[C@H](N)C(O)=O.NC(=O)[C@H](N)CCC(O)=O MWTAHJPEYZBMCZ-FLLNTKIGSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-PGYHGBPZSA-N 2-amino-3-O-[(R)-1-carboxyethyl]-2-deoxy-D-glucopyranose Chemical compound OC(=O)[C@@H](C)O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O MSFSPUZXLOGKHJ-PGYHGBPZSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000015689 E-Selectin Human genes 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001375 Facial Neuralgia Diseases 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100035414 Neurofascin Human genes 0.000 description 1
- 101710189786 Neurofascin Proteins 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000009246 art therapy Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 208000012790 cranial neuralgia Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 229940042385 glatiramer Drugs 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007188 immune regulating pathway Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000011488 interferon-alpha production Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229940124625 intravenous corticosteroids Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011867 re-evaluation Methods 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011300 routine therapy Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Photographic Developing Apparatuses (AREA)
Priority Applications (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ577731A NZ577731A (en) | 2009-06-16 | 2009-06-16 | Compositions and methods for treatment of multiple sclerosis |
| US12/639,733 US8389479B2 (en) | 2009-06-16 | 2009-12-16 | Compositions and methods for treatment of multiple sclerosis |
| CA2688766A CA2688766C (en) | 2009-06-16 | 2009-12-17 | Compositions and methods for treatment of multiple sclerosis |
| BRPI1009606A BRPI1009606A2 (pt) | 2009-06-16 | 2010-01-16 | método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição |
| CN201080026791.5A CN102458476B (zh) | 2009-06-16 | 2010-01-16 | 用于治疗多发性硬化症的组合物及方法 |
| HK12107888.6A HK1167101B (en) | 2009-06-16 | 2010-06-16 | Compositions and methods for treatment of multiple sclerosis |
| PCT/NZ2010/000112 WO2010147484A1 (en) | 2009-06-16 | 2010-06-16 | Compositions and methods for treatment of multiple sclerosis |
| IN167DEN2012 IN2012DN00167A (enExample) | 2009-06-16 | 2010-06-16 | |
| DK10789788.6T DK2442832T3 (da) | 2009-06-16 | 2010-06-16 | Sammensætninger og fremgangsmåder til behandling af dissemineret sclerose |
| ES10789788.6T ES2521565T3 (es) | 2009-06-16 | 2010-06-16 | Composiciones y métodos para el tratamiento de la esclerosis múltiple |
| PT107897886T PT2442832E (pt) | 2009-06-16 | 2010-06-16 | Composições e métodos para tratamento da esclerose múltipla |
| EP10789788.6A EP2442832B1 (en) | 2009-06-16 | 2010-06-16 | Compositions and methods for treatment of multiple sclerosis |
| JP2012516022A JP5646617B2 (ja) | 2009-06-16 | 2010-06-16 | 多発性硬化症の治療のための組成物および方法 |
| PL10789788T PL2442832T3 (pl) | 2009-06-16 | 2010-06-16 | Kompozycje i sposoby do leczenia stwardnienia rozsianego |
| AU2010260585A AU2010260585B2 (en) | 2009-06-16 | 2010-06-16 | Compositions and methods for treatment of Multiple Sclerosis |
| HRP20141035AT HRP20141035T1 (hr) | 2009-06-16 | 2010-06-16 | Sastavi i metode za lijeäśenje multiple skleroze |
| SI201030779T SI2442832T1 (sl) | 2009-06-16 | 2010-06-16 | Sestavki in postopki za zdravljenje multiple skleroze |
| MX2011013661A MX2011013661A (es) | 2009-06-16 | 2010-06-16 | Composiciones y metodos para el tratamiento de esclerosis multiple. |
| IL216993A IL216993A (en) | 2009-06-16 | 2011-12-15 | Pharmaceuticals Containing Microparticle Cross-linked Murmyl Peptide for the Treatment of Multiple Sclerosis |
| CY20141100908T CY1115714T1 (el) | 2009-06-16 | 2014-11-03 | Συνθεσεις και μεθοδοι για τη θεραπεια της πολλαπλης σκληρυνσης |
| SM201400165T SMT201400165B (it) | 2009-06-16 | 2014-11-04 | Composizioni e metodi per il trattamento di sclerosi multipla |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ577731A NZ577731A (en) | 2009-06-16 | 2009-06-16 | Compositions and methods for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ577731A true NZ577731A (en) | 2010-08-27 |
Family
ID=42646236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ577731A NZ577731A (en) | 2009-06-16 | 2009-06-16 | Compositions and methods for treatment of multiple sclerosis |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8389479B2 (enExample) |
| EP (1) | EP2442832B1 (enExample) |
| JP (1) | JP5646617B2 (enExample) |
| CN (1) | CN102458476B (enExample) |
| AU (1) | AU2010260585B2 (enExample) |
| BR (1) | BRPI1009606A2 (enExample) |
| CA (1) | CA2688766C (enExample) |
| CY (1) | CY1115714T1 (enExample) |
| DK (1) | DK2442832T3 (enExample) |
| ES (1) | ES2521565T3 (enExample) |
| HR (1) | HRP20141035T1 (enExample) |
| IL (1) | IL216993A (enExample) |
| IN (1) | IN2012DN00167A (enExample) |
| MX (1) | MX2011013661A (enExample) |
| NZ (1) | NZ577731A (enExample) |
| PL (1) | PL2442832T3 (enExample) |
| PT (1) | PT2442832E (enExample) |
| SI (1) | SI2442832T1 (enExample) |
| SM (1) | SMT201400165B (enExample) |
| WO (1) | WO2010147484A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2719252C (en) * | 2008-04-01 | 2016-01-19 | Innate Therapeutics Limited | Anti-infective agents comprising muramyl dipeptide microparticles and uses thereof |
| JP5847188B2 (ja) | 2010-10-25 | 2016-01-20 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | ｓＶＣＡＭおよび／またはｓＭＡｄＣＡＭレベルの差を関連付けることにより、アルファ−４インテグリン活性の差を決定するための方法 |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| CA2926507A1 (en) * | 2015-10-06 | 2017-04-06 | Innate Immunotherapeutics Limited | Compositions and methods for protection and/or repair of the nervous system |
| WO2017059486A1 (en) * | 2015-10-06 | 2017-04-13 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of epilepsy |
| WO2017070731A1 (en) * | 2015-10-28 | 2017-05-04 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of alzheimer's disease |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| HRP20250396T1 (hr) | 2016-08-31 | 2025-05-23 | Mapi Pharma Ltd. | Depo sustavi koji sadrže glatiramer acetat |
| AU2018242998B2 (en) | 2017-03-26 | 2023-11-02 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| CA3099946A1 (en) * | 2018-05-18 | 2019-11-21 | Universite Laval | Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease |
| US12109271B2 (en) | 2018-07-03 | 2024-10-08 | University Of Florida Research Foundation, Incorporated | Microparticle systems and their use for the treatment of multiple sclerosis |
| US20230190570A1 (en) * | 2020-06-22 | 2023-06-22 | Otivio As | Methods for treating spasticity using anti-spasmodic compositions and negative pressure therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2268372C (en) * | 1996-10-10 | 2012-11-27 | Probe International | Compositions and methods for treating viral infections |
| BRPI0512921A (pt) * | 2004-07-01 | 2008-04-22 | Den Kgl Veterinaer Og Landboho | processo para tratamento e profilaxia de ms |
| US8603978B2 (en) * | 2006-12-01 | 2013-12-10 | The United States of America, as represented by the Secretary, Department of Health and Humand Services | Use of muramyl dipeptide (MDP) for treating inflammation |
| JP2008251608A (ja) | 2007-03-29 | 2008-10-16 | Casio Comput Co Ltd | 半導体装置およびその製造方法 |
| WO2008150181A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treating anthrax exposure associated conditions |
| WO2008150182A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treatment of anthrax |
-
2009
- 2009-06-16 NZ NZ577731A patent/NZ577731A/en not_active IP Right Cessation
- 2009-12-16 US US12/639,733 patent/US8389479B2/en not_active Expired - Fee Related
- 2009-12-17 CA CA2688766A patent/CA2688766C/en not_active Expired - Fee Related
-
2010
- 2010-01-16 CN CN201080026791.5A patent/CN102458476B/zh not_active Expired - Fee Related
- 2010-01-16 BR BRPI1009606A patent/BRPI1009606A2/pt not_active Application Discontinuation
- 2010-06-16 HR HRP20141035AT patent/HRP20141035T1/hr unknown
- 2010-06-16 PL PL10789788T patent/PL2442832T3/pl unknown
- 2010-06-16 JP JP2012516022A patent/JP5646617B2/ja not_active Expired - Fee Related
- 2010-06-16 DK DK10789788.6T patent/DK2442832T3/da active
- 2010-06-16 SI SI201030779T patent/SI2442832T1/sl unknown
- 2010-06-16 IN IN167DEN2012 patent/IN2012DN00167A/en unknown
- 2010-06-16 AU AU2010260585A patent/AU2010260585B2/en not_active Ceased
- 2010-06-16 MX MX2011013661A patent/MX2011013661A/es active IP Right Grant
- 2010-06-16 ES ES10789788.6T patent/ES2521565T3/es active Active
- 2010-06-16 WO PCT/NZ2010/000112 patent/WO2010147484A1/en not_active Ceased
- 2010-06-16 EP EP10789788.6A patent/EP2442832B1/en active Active
- 2010-06-16 PT PT107897886T patent/PT2442832E/pt unknown
-
2011
- 2011-12-15 IL IL216993A patent/IL216993A/en not_active IP Right Cessation
-
2014
- 2014-11-03 CY CY20141100908T patent/CY1115714T1/el unknown
- 2014-11-04 SM SM201400165T patent/SMT201400165B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI1009606A2 (pt) | 2016-10-11 |
| PL2442832T3 (pl) | 2015-01-30 |
| EP2442832A1 (en) | 2012-04-25 |
| IL216993A (en) | 2016-03-31 |
| JP2012530132A (ja) | 2012-11-29 |
| DK2442832T3 (da) | 2014-11-10 |
| JP5646617B2 (ja) | 2014-12-24 |
| IN2012DN00167A (enExample) | 2015-04-17 |
| AU2010260585A8 (en) | 2012-06-14 |
| US20100317589A1 (en) | 2010-12-16 |
| CN102458476B (zh) | 2014-08-20 |
| ES2521565T3 (es) | 2014-11-12 |
| HK1167101A1 (en) | 2013-02-01 |
| EP2442832B1 (en) | 2014-08-06 |
| IL216993A0 (en) | 2012-02-29 |
| SI2442832T1 (sl) | 2014-12-31 |
| PT2442832E (pt) | 2014-11-11 |
| AU2010260585B2 (en) | 2013-02-21 |
| WO2010147484A8 (en) | 2012-07-19 |
| EP2442832A4 (en) | 2013-07-03 |
| MX2011013661A (es) | 2012-05-22 |
| CY1115714T1 (el) | 2017-01-25 |
| HRP20141035T1 (hr) | 2014-12-19 |
| WO2010147484A1 (en) | 2010-12-23 |
| SMT201400165B (it) | 2015-01-15 |
| CA2688766C (en) | 2015-06-30 |
| US8389479B2 (en) | 2013-03-05 |
| CN102458476A (zh) | 2012-05-16 |
| CA2688766A1 (en) | 2010-12-16 |
| AU2010260585A1 (en) | 2012-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010260585B2 (en) | Compositions and methods for treatment of Multiple Sclerosis | |
| JP6208235B2 (ja) | 多発性硬化症治療のためのビオチンの使用 | |
| TW201119645A (en) | Low frequency glatiramer acetate therapy | |
| WO2014019268A1 (zh) | 一种促进神经损伤修复的药物组合物及其应用 | |
| JP2008519847A (ja) | 運動障害の治療方法 | |
| JP2001511121A (ja) | コポリマー１の摂取又は吸入を通じての多発性硬化症の治療 | |
| JPWO2003061688A1 (ja) | 新規鎮痛剤 | |
| JP2019533731A (ja) | Ｃｂｄとコパキソンの併用療法 | |
| RU2701720C1 (ru) | Комбинации пальмитоилэтаноламида для лечения хронической боли | |
| KR20200101948A (ko) | 신경계 질환 치료제 | |
| KR20170131543A (ko) | 근위축성 측삭 경화증을 치료하기 위한 비오틴 | |
| RU2180591C2 (ru) | Средство для лечения сексуальных дисфункций у мужчин | |
| HK1167101B (en) | Compositions and methods for treatment of multiple sclerosis | |
| CN111803487B (zh) | 银杏萜内酯在制备预防和/或治疗吉兰-巴雷综合征药物中的用途 | |
| US20060020037A1 (en) | Tazarotenic acid and esters thereof for treating autism | |
| ES2447829T3 (es) | Combinación para el tratamiento de la osteoartritis | |
| WO2020207398A1 (zh) | 银杏萜内酯在制备预防和/或治疗吉兰-巴雷综合征药物中的用途 | |
| Sullivan-Whalen et al. | Psoriasis: hope for the future | |
| JP2021530567A (ja) | 安息香酸塩または安息香酸誘導体を含む、抗ｎ−メチル−ｄ−アスパラギン酸受容体脳炎を予防または治療するための医薬組成物 | |
| RU2564907C1 (ru) | Способ лечения больных красным плоским лишаем | |
| CN110101845A (zh) | 鸢尾素在制备防治术后认知功能障碍以及血脑屏障受损所介导脑病的药物中的应用 | |
| CN109999179A (zh) | 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用 | |
| JP2023539391A (ja) | セスキテルペンラクトン系化合物の視神経炎治療薬の製造における使用 | |
| WO2019135363A1 (ja) | 腱滑膜病変を主体とした疾患の治療薬 | |
| Rellosa et al. | Profound weakness in a young woman |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| S881 | Correction of error according section 88(1) (mistake in register by reason of an error or omission on the part of the patent office) |
Free format text: CORRECTION TO THE FILING DATE (22) |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 JUN 2017 BY SHELSTON IP Effective date: 20140610 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUN 2018 BY SHELSTON IP PTY LTD Effective date: 20170512 |
|
| LAPS | Patent lapsed |